JY
INDV icon

Jeff Yass’s Indivior Pharmaceuticals INDV Stock Holding History

Jeff Yass’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.56M Sell
62,340
-97,757
-61% -$3.55M ﹤0.01% 5930
2026
Q1 		$4.88M Buy
160,097
+111,412
+229% +$3.68M ﹤0.01% 4270
2025
Q4 		$1.75M Sell
48,685
-553,378
-92% -$16.9M ﹤0.01% 5926
2025
Q3 		$14.5M Buy
602,063
+115,176
+24% +$2.41M ﹤0.01% 2541
2025
Q2 		$7.18M Sell
486,887
-1,785,055
-79% -$20.8M ﹤0.01% 3338
2025
Q1 		$21.7M Buy
2,271,942
+2,050,248
+925% +$21.6M ﹤0.01% 1679
2024
Q4 		$2.76M Sell
221,694
-6,199
-3% -$63.8K ﹤0.01% 4632
2024
Q3 		$2.22M Sell
227,893
-8,159
-3% -$95.6K ﹤0.01% 5061
2024
Q2 		$3.81M Buy
236,052
+34,459
+17% +$622K ﹤0.01% 3890
2024
Q1 		$4.32M Buy
201,593
+175,773
+681% +$3.3M ﹤0.01% 3878
2023
Q4 		$395K Hold
25,820
– – ﹤0.01% 9225
2023
Q3 		$583K Buy
+25,820
New +$589K ﹤0.01% 7874

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jeff Yass's INDV Position: Q2 2026 in Review

Jeff Yass reduced its Indivior Pharmaceuticals (INDV) stake by 61% in Q2 2026, selling an estimated $3.55M and leaving 62,340 shares worth $2.56M. The position accounts for ﹤0.01% of the portfolio, ranked #5930.

Jeff Yass first reported a position in INDV in Q3 2023 and has held it in 12 quarters since. The position peaked at $21.7M in Q1 2025. 336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Jeff Yass held 62,340 shares of Indivior Pharmaceuticals worth $2.56M as of Q2 2026.
  • Jeff Yass sold 97,757 Indivior Pharmaceuticals shares in Q2 2026, an estimated $3.55M.
  • Indivior Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #5930 holding.
  • Jeff Yass first reported a position in Indivior Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Jeff Yass's Indivior Pharmaceuticals position peaked at $21.7M in Q1 2025.
  • 336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.